Johnson & Johnson JNJ:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 99.90 | -0.19 -0.19% | 2.80% | 8,610,725 | 6.1M |
Recent News Headlines for Johnson & Johnson
- Financial Results, Campaign Launch, and New Steps in Facility Planning - Research Reports on Johnson & Johnson, Merck, AstraZeneca, Novartis and Teva
Editor Note: For more information about this release, please scroll to bottom NEW YORK, July 23, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AstraZeneca plc (NYSE: AZN), Novartis AG (NYSE: NVS) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5022-100free.
- Johnson & Johnson Announces $5 Billion Share Repurchase Program
NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The company had approximately 2,822.6 million shares of common stock outstanding as of June 29, 2014.
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014
NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on September 9, 2014 to shareholders of record at the close of business on August 26, 2014. The ex-dividend date is August 22, 2014.
- Technical Pointers on Pharma Equities -- AbbVie, Johnson and Johnson, Merck, Bristol-Myers Squibb, and Eli Lilly
- Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
- Biotechnology Sector Trends Higher with -2-
- Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver
- Johnson & Johnson Reports 2014 Second-Quarter -4-
- Johnson & Johnson Reports 2014 Second-Quarter Results:
- Johnson & Johnson Reports 2014 Second-Quarter -2-
- Johnson & Johnson Reports 2014 Second-Quarter -3-
- Johnson & Johnson Reports 2014 Second-Quarter -5-
- Johnson & Johnson Reports 2014 Second-Quarter -6-
- InvestorsObserver releases comments on Google, Johnson & Johnson, JP Morgan Chase, eBay, and KB Home
- New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo